A
Alcista
Alcista · 25%EXEL
$51.94
Precio del escenario
$62.830
+1.897 (+3.02%)Al cierre
Loading chart…
- Máximo
- 63.310
- Apertura
- 61.690
- Precio medio ponderado por volumen
- 62.47
- Volumen
- 2.77M
- Capitalización
- 6.56B
- Mínimo
- 61.280
- Importe
- 173.31M
- EV/EBITDA, TTM
- 12.76
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Análisis de IA of Exelixis Inc (EXEL)
ComprarExelixis Inc is a good buy right now due to its current price of $59.86, which is below the analyst price targets of $51 and $54, indicating potential upside. The stock has shown strong performance with a year-to-date change of +37.36% and a 1-year change of +55.72%. However, the RSI is at 73.058, suggesting it may be overbought, which is a risk to consider.
Recomendaciones de analistas (10)
-29.83% Potencial de caída
Comprar
6 Comprar
4 Mantener
0 Vender
Actual: 62.83
Mínimo
30.00
Promedio
44.09
Máximo
52.00
RBC Capital
Sector Perform
$51
2026-10-09
RBC Capital
2026-10-09
Precio objetivo
$51
Sector Perform
RBC Capital
Sector Perform
$45
2026-10-08
RBC Capital
2026-10-08
Precio objetivo
$45
Sector Perform
Truist
Mantener
$54
2026-10-07
Truist
2026-10-07
Precio objetivo
$54
Mantener
William Blair
Superar al mercado
—
2026-09-11
William Blair
2026-09-11
Precio objetivo
—
Superar al mercado
Leerink
Market Perform
$52
2026-08-06
Leerink
2026-08-06
Precio objetivo
$52
Market Perform
Métricas de valoración
El PER previsto actual de Exelixis Inc (EXEL) es 13.55, frente a su media de 5 años de 23.09.
Escenarios de precio de Alphio AI para EXEL
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con EXEL en cartera
Cronología de eventos
Noticias
8.510-14PRnewswireRapid Growth in Cancer Drug Market Forecasted
9.009-11stocktwitsFDA Extends Exelixis Drug Review Deadline to 2027
4.509-11Yahoo FinanceHealthcare Stocks Decline Late Friday
9.009-11NewsfilterFDA Extends Exelixis NDA Review for Zanzalintinib to March 2027
7.509-03NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Regulatory Milestones
Preguntas frecuentes sobre EXEL, respondidas por Alphio AI
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Exelixis Inc is a good buy right now due to its current price of $59.86, which is below the analyst price targets of $51 and $54, indicating potential upside. The stock has shown strong performance with a year-to-date change of +37.36% and a 1-year change of +55.72%. However, the RSI is at 73.058, suggesting it may be overbought, which is a risk to consider.
10 analysts cover EXEL: 6 rate it Buy, 4 Hold and 0 Sell. The average price target is 44.09.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.